Issue Archive
Table of Contents
EDITORIAL
ADVANCES VIEWPOINT
CLINICAL TRIALS AND OBSERVATIONS
        
        Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
        
        Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
        
        Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
    
            HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
LYMPHOID NEOPLASIA
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
MYELOID NEOPLASIA
JAK2V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
RED CELLS, IRON, AND ERYTHROPOIESIS
            Effects of mitapivat-mediated pyruvate kinase activation in sickle cell disease. Mitapivat (AG-348) is an oral allosteric activator of pyruvate kinase (PK), a key enzyme in RBC glycolysis. PK activation decreases 2,3-DPG levels and increases ATP levels in RBCs. This study showed that mitapivat decreased parameters of hemolysis, RBC sickling and vaso-occlusive events and increased hemoglobin (Hb) level and Hb-oxygen affinity.1,3-DPG, 1,3-Disphosphoglycerate; ADP, adenosine diphosphate; P, phosphate; 2,3-DPG, 2,3-diphosphoglycerate; ATP, adenosine triphosphate; 3-PG, 3-Phosphoglycerate; PEP, phosphoenolpyruvate; RBC, red blood cell; Hb, hemoglobin.
        
        One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
RESEARCH LETTERS
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia
        
        Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        COMMENTARIES
- 
        
            Cover Image
        
        
Cover Image
            Representative image of immunohistochemical staining of myeloid leukemia cell differentiation protein in diagnostic samples from follicular lymphoma. Magnification 20x. See the article by Enemark et al.
 - PDF Icon Front MatterFront Matter
 - PDF Icon Editorial BoardEditorial Board
 
Advertisement intended for health care professionals
Advertisement intended for health care professionals
                    
















